Cargando…

AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications

With the development of (68)Ga and (177)Lu radiochemistry, theranostic approaches in modern nuclear medicine enabling patient-centered personalized medicine applications have been growing in the last decade. In conjunction with the search for new relevant molecular targets, the design of innovative...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fersing, Cyril, Masurier, Nicolas, Rubira, Léa, Deshayes, Emmanuel, Lisowski, Vincent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879111/ https://www.ncbi.nlm.nih.gov/pubmed/35215346 http://dx.doi.org/10.3390/ph15020234

Ejemplares similares

Development and Implementation of a Professional Practices Evaluation during Radiopharmaceuticals Administration
por: Donzé, Charlotte, et al.
Publicado: (2022)

Thienopyrimidine: A Promising Scaffold to Access Anti-Infective Agents
por: Lagardère, Prisca, et al.
Publicado: (2021)

(225)Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic
por: Rubira, Léa, et al.
Publicado: (2023)

The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker
por: Holik, Holis Abdul, et al.
Publicado: (2022)

Implementation and validation of an in-house combined fluorescein/media-fill test to qualify radiopharmacy operators
por: Fersing, Cyril, et al.
Publicado: (2021)

Boosting Bismuth(III) Complexation for Targeted α‐Therapy (TAT) Applications with the Mesocyclic Chelating Agent AAZTA
por: Horváth, Dávid, et al.
Publicado: (2022)

A Comprehensive Review of Non-Covalent Radiofluorination Approaches Using Aluminum [(18)F]fluoride: Will [(18)F]AlF Replace (68)Ga for Metal Chelate Labeling?
por: Fersing, Cyril, et al.
Publicado: (2019)

Innovation in Radionuclide Therapy for the Treatment of Prostate Cancers: Radiochemical Perspective and Recent Therapeutic Practices
por: Deshayes, Emmanuel, et al.
Publicado: (2023)

Modern Developments in Bifunctional Chelator Design for Gallium Radiopharmaceuticals
por: Davey, Patrick R. W. J., et al.
Publicado: (2022)

AAZTA(5)/AAZTA(5)-TOC: synthesis and radiochemical evaluation with (68)Ga, (44)Sc and (177)Lu
por: Sinnes, Jean-Philippe, et al.
Publicado: (2019)

Surprising Complexity of the [Gd(AAZTA)(H(2)O)(2)](−) Chelate Revealed by NMR in the Frequency and Time Domains
por: Lalli, Daniela, et al.
Publicado: (2021)

Effect of the versatile bifunctional chelator AAZTA(5) on the radiometal labelling properties and the in vitro performance of a gastrin releasing peptide receptor antagonist
por: Hofstetter, Michael, et al.
Publicado: (2020)

Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms
por: Fani, Melpomeni, et al.
Publicado: (2017)

Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy
por: Barca, Cristina, et al.
Publicado: (2021)

Derivatives of GdAAZTA Conjugated to Amino Acids: A Multinuclear and Multifrequency NMR Study
por: Lalli, Daniela, et al.
Publicado: (2022)

Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals()
por: Cai, Zhengxin, et al.
Publicado: (2013)

Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach
por: Lahnif, Hanane, et al.
Publicado: (2021)

First‐Generation Bispidine Chelators for (213)Bi(III) Radiopharmaceutical Applications
por: Bruchertseifer, Frank, et al.
Publicado: (2020)

Editorial: Innovative Radiopharmaceuticals in Oncology and Neurology
por: Barbet, Jacques, et al.
Publicado: (2017)

Click-to-Chelate: Development of Technetium and Rhenium-Tricarbonyl Labeled Radiopharmaceuticals
por: Kluba, Christiane A., et al.
Publicado: (2013)

Theranostic digital twins for personalized radiopharmaceutical therapies: Reimagining theranostics via computational nuclear oncology
por: Rahmim, Arman, et al.
Publicado: (2022)

Developing scandium and yttrium coordination chemistry to advance theranostic radiopharmaceuticals
por: Carter, Korey P., et al.
Publicado: (2020)

[(111)In]In/[(177)Lu]Lu-AAZTA(5)-LM4 SST(2)R-Antagonists in Cancer Theranostics: From Preclinical Testing to First Patient Results
por: Nock, Berthold A., et al.
Publicado: (2023)

Innovative radiopharmaceuticals in oncology and neurology
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2017)

Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples
por: Kolenc Peitl, Petra, et al.
Publicado: (2019)

Unusual Focal Lung Uptake without CT Abnormality on a Bone Scan: What Might It Mean?
por: Eberlé, Marie-Claude, et al.
Publicado: (2022)

Hydroxypyridinone Chelators: From Iron Scavenging to Radiopharmaceuticals for PET Imaging with Gallium-68
por: Cusnir, Ruslan, et al.
Publicado: (2017)

Future Prospective of Radiopharmaceuticals from Natural Compounds Using Iodine Radioisotopes as Theranostic Agents
por: Nurhidayah, Wiwit, et al.
Publicado: (2022)

Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Airaksinen, A, et al.
Publicado: (2016)

Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Domnanich, Katharina, et al.
Publicado: (2014)

Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Dorrer, H, et al.
Publicado: (2011)

Application of Stem Cell-Derived Extracellular Vesicles as an Innovative Theranostics in Microbial Diseases
por: Keshavarz Alikhani, Hani, et al.
Publicado: (2021)

Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma
por: Foster, Alexandra, et al.
Publicado: (2021)

IS528 Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Koester, Ulli, et al.
Publicado: (2018)

IS528 Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Köster, Ulli
Publicado: (2017)

Alternative Chelator for (89)Zr Radiopharmaceuticals: Radiolabeling and Evaluation of 3,4,3-(LI-1,2-HOPO)
por: Deri, Melissa A., et al.
Publicado: (2014)

Theranostic Role of (32)P-ATP as Radiopharmaceutical for the Induction of Massive Cell Death within Avascular Tumor Core
por: Galiè, Mirco, et al.
Publicado: (2017)

3p-C-NETA: A versatile and effective chelator for development of Al(18)F-labeled and therapeutic radiopharmaceuticals
por: Ahenkorah, Stephen, et al.
Publicado: (2022)

4-Substituted Thieno[3,2-d]pyrimidines as Dual-Stage Antiplasmodial Derivatives
por: Lagardère, Prisca, et al.
Publicado: (2022)

Preparation, Characterization, and Preliminary Imaging Study of [(188)Re]Re-Ibandronate as a Novel Theranostic Radiopharmaceutical for Bone Metastasis
por: Xu, Tingting, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t00hkqvqhb2ieu4omehdbim141